Exchange: NASDAQ·Updated 07:30 PM EST

SABS News

News
all
press releases
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock Has Average Price Target of $12.00
Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a h...
MarketBeat
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock Has Average Price Target of $12.00
Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a h...
MarketBeat
More News
SAB Biotherapeutics, Inc. (SABS) Presents at UBS Global Biopharma Conference 2026 Transcript...
SeekingAlpha
Novo has 44 abstracts at EASD, including CagriSema analyses and Phase 2b Zenagamtide results.
Stocktwits
SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment...
Yahoo! Finance: News
Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target...
Yahoo! Finance: News
Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS...
Yahoo! Finance: News
Biotechnology and healthcare innovation dominated investor conversations today as multiple companies delivered meaningful corporate, clinical, regulatory, and commercialization updates. From artificial intelligence-powered drug discovery platforms to neuro-oncology, regenerative medicine, wound care technologies, and autoimmune disease therapies, investors focused on companies that could potentially benefit from major industry trends while advancing important milestones of their own. $CUPR, $HYFT, $NTHI, $RGNT, $GELS, $SABS
24-7 Market News
The HHS confirmed that one American passenger evacuated from the MV Hondius cruise ship tested mildly positive for the Andes strain of hantavirus.
Stocktwits
SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, five have assigned a buy reco...
MarketBeat
SAB Biotherapeutics (NASDAQ:SABS) will be releasing its Q1 2026 earnings before the market opens on Friday, May 8. (View Earnings Report at...
MarketBeat

Advertisement|Remove ads.